EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 174 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 1.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $121 | -65.3% | 6,200 | -49.7% | 0.00% | -100.0% |
| Q1 2023 | $349 | +7.1% | 12,316 | +10.3% | 0.00% | 0.0% |
| Q4 2022 | $326 | -99.9% | 11,165 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $295,000 | -39.8% | 11,165 | +1.2% | 0.00% | 0.0% |
| Q2 2022 | $490,000 | -5.2% | 11,037 | +8.4% | 0.00% | 0.0% |
| Q1 2022 | $517,000 | +6.8% | 10,180 | +7.2% | 0.00% | 0.0% |
| Q4 2021 | $484,000 | -10.5% | 9,494 | -1.5% | 0.00% | 0.0% |
| Q3 2021 | $541,000 | +31.3% | 9,641 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $412,000 | +2.5% | 9,641 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $402,000 | -25.3% | 9,641 | -16.5% | 0.00% | 0.0% |
| Q4 2020 | $538,000 | +3.9% | 11,550 | -5.3% | 0.00% | 0.0% |
| Q3 2020 | $518,000 | -14.8% | 12,200 | -3.6% | 0.00% | 0.0% |
| Q2 2020 | $608,000 | -3.3% | 12,661 | -7.4% | 0.00% | -50.0% |
| Q1 2020 | $629,000 | -16.6% | 13,675 | +8.0% | 0.00% | 0.0% |
| Q4 2019 | $754,000 | -6.5% | 12,658 | -12.7% | 0.00% | 0.0% |
| Q2 2019 | $806,000 | +5.1% | 14,493 | -4.7% | 0.00% | 0.0% |
| Q1 2019 | $767,000 | +48.1% | 15,209 | +9.0% | 0.00% | +100.0% |
| Q4 2018 | $518,000 | -46.4% | 13,948 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $967,000 | +20.0% | 13,948 | +31.0% | 0.00% | 0.0% |
| Q2 2018 | $806,000 | +43.7% | 10,648 | 0.0% | 0.00% | +100.0% |
| Q1 2018 | $561,000 | -9.1% | 10,648 | -7.8% | 0.00% | 0.0% |
| Q4 2017 | $617,000 | -9.0% | 11,546 | 0.0% | 0.00% | -50.0% |
| Q3 2017 | $678,000 | -25.5% | 11,546 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $910,000 | -2.4% | 11,546 | +2.7% | 0.00% | -33.3% |
| Q1 2017 | $932,000 | +14.5% | 11,244 | +9.6% | 0.00% | +50.0% |
| Q4 2016 | $814,000 | -46.1% | 10,263 | -52.5% | 0.00% | 0.0% |
| Q3 2016 | $1,510,000 | +4094.4% | 21,586 | +2216.1% | 0.00% | – |
| Q2 2016 | $36,000 | -5.3% | 932 | 0.0% | 0.00% | – |
| Q1 2016 | $38,000 | -54.2% | 932 | 0.0% | 0.00% | – |
| Q4 2015 | $83,000 | +20.3% | 932 | 0.0% | 0.00% | – |
| Q3 2015 | $69,000 | – | 932 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |